Concord Drugs Ltd (NSE: CONCORD), ISIN INE858L01010 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
CONCORD last traded at ₹72.98 (+5.94%), with a 52-week range of ₹49.00 to ₹92.52 (as of 30 Jul 2026).
Shareholding as of Dec 2025: promoters 54.39%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 15/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.